Preclinical studies of prototype Rabies DNA Vaccine

Abstract

The results of the preclinical studies of the experimental samples of the prototype immune-biological preparation (Rabies DNA Vaccine) based on the rabies virus glycoprotein genome fragment modified with the signal sequences have been reported. The LD₅₀ values were planned to have been estimated using the results of the observations 24 h, 7 days, and 14 days after the drug administration; however, it appeared impossible to make any calculations because of the low toxicity of the preparation; thus, the vaccine was delivered at the maximum dose comprising 2 g/kg. The intensive growth rates in mice and rabbits confirmed the absence of the toxic effects of the tested preparations on the animal organisms. The live weight at the end of the experiment did not decrease as compared to the initial live weight. The complete blood count and biochemical tests in mice and rabbits did not reveal any deviations from the norm. The internal organs were flexible and have an elastic consistence; no significant statistical difference in the weights of the mouse internal organs (liver and brain) was ascertained. In the histological material, no pathomorphological changes of the organ cells were revealed.